Foghorn Therapeutics Inc. develops precision therapeutics for serious diseases by targeting the chromatin regulatory system and correcting abnormal gene expression. The company’s news centers on oncology programs derived from its Gene Traffic Control® platform, including FHD-909, a selective SMARCA2 inhibitor for SMARCA4-mutant cancers, and selective CBP, EP300 and ARID1B degrader programs across ER+ breast cancer, multiple myeloma and other hematologic malignancies.
Recurring updates also cover the company’s collaboration with Lilly, preclinical data presentations, financial results, registered direct financing activity, executive appointments and investor-conference participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at the Nasdaq Headquarters in New York City. The session, featuring President and CEO Adrian Gottschalk, will take place at 1:30 p.m. ET. Foghorn is focused on developing innovative medicines that address abnormal gene expression, particularly in oncology, through its Gene Traffic Control platform. A webcast of the panel discussion will be available on Foghorn's website for 30 days following the event. For more details, visit www.foghorntx.com.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) has paused enrollment in its FHD-609 clinical study targeting synovial sarcoma and SMARCB1-deleted tumors after a serious QTc prolongation event occurred in a patient at the second highest dose. The dose escalation phase is completed, and a maximum tolerated dose has been identified. The FDA has placed the study on a partial clinical hold but allows current patients to continue treatment. The company is not planning to pursue a dose expansion study independently at this time. The update highlights Foghorn's commitment to patient safety and regulatory compliance.